CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy – Reuters

June 16 (Reuters) – German biotech CureVac NV (5CV.DE) said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study’s main goal and throwing in doubt the pot… [+4424 chars]